Cross-Seal IDE Trial: Prospective, Multicenter, Single-Arm Study of the Cross-Seal Suture-Mediated Vascular Closure Device System

医学 外科 止血 经皮 临床终点 血管闭合器 纤维接头 随机对照试验
作者
Prakash Krishnan,Serdar Farhan,Frank Zidar,Zvonimir Krajcer,Christopher Metzger,Samir Kapadia,Erin Moore,Tamim Nazif,Ty Garland,Ming Zhang,Sahil Khera,Mel J. Sharafuddin,Virendra I. Patel,J. Michael Bacharach,Paul Coady,Marc L. Schermerhorn,Murray L. Shames,Saum Rahimi,Jean M. Panneton,Craig Elkins,Mazin I. Foteh
出处
期刊:Circulation-cardiovascular Interventions [Ovid Technologies (Wolters Kluwer)]
卷期号:17 (6)
标识
DOI:10.1161/circinterventions.123.013842
摘要

BACKGROUND: An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device in obtaining hemostasis at the target limb access site following interventional procedures using 8F to 18F procedural sheaths. METHODS: The Cross-Seal IDE trial (Investigational Device Exemption) was a prospective, single-arm, multicenter study in subjects undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheaths. The primary efficacy end point was time to hemostasis at the target limb access site. The primary safety end point was freedom from major complications of the target limb access site within 30 days post procedure. RESULTS: A total of 147 subjects were enrolled between August 9, 2019, and March 12, 2020. Transcatheter aortic valve replacement was performed in 53.7% (79/147) and percutaneous endovascular abdominal/thoracic aortic aneurysm repair in 46.3% (68/147) of subjects. The mean sheath ID was 15.5±1.8 mm. The primary effectiveness end point of time to hemostasis was 0.4±1.4 minutes. An adjunctive intervention was required in 9.2% (13/142) of subjects, of which 2.1% (3/142) were surgical and 5.6% (8/142) endovascular. Technical success was achieved in 92.3% (131/142) of subjects. Freedom from major complications of the target limb access site was 94.3% (83/88). CONCLUSIONS: In selected patients undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheath, Cross-Seal suture-mediated vascular closure device achieved favorable effectiveness and safety in the closure of the large-bore arteriotomy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03756558.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ChandlerZB完成签到,获得积分10
刚刚
刘璇2完成签到,获得积分10
1秒前
啦啦啦发布了新的文献求助10
3秒前
bkagyin应助txh12323采纳,获得30
6秒前
7秒前
yiqifan完成签到,获得积分0
7秒前
刘璇1完成签到,获得积分10
9秒前
浅笑完成签到,获得积分10
9秒前
13秒前
13秒前
雪烟飞扬完成签到,获得积分10
15秒前
小巧问筠应助妥妥酱采纳,获得10
15秒前
独特大米发布了新的文献求助10
19秒前
田改完成签到,获得积分10
19秒前
lx123abc完成签到 ,获得积分10
20秒前
Owen应助神奇的种子采纳,获得10
20秒前
小篆完成签到 ,获得积分10
22秒前
22秒前
嘎嘎发布了新的文献求助10
22秒前
毛毛应助独特大米采纳,获得20
23秒前
25秒前
vicky完成签到,获得积分10
27秒前
缥缈孤兰完成签到,获得积分10
29秒前
29秒前
傻大发布了新的文献求助20
29秒前
lichun410932发布了新的文献求助10
30秒前
开心的盼望完成签到 ,获得积分10
30秒前
花花完成签到,获得积分10
30秒前
32秒前
33秒前
35秒前
vidgers完成签到 ,获得积分10
35秒前
华仔应助就当野人算了采纳,获得10
35秒前
36秒前
结实煎饼发布了新的文献求助200
38秒前
38秒前
传奇3应助ww采纳,获得10
38秒前
40秒前
41秒前
42秒前
高分求助中
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Machine Learning for Polymer Informatics 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
2024 Medicinal Chemistry Reviews 480
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3222497
求助须知:如何正确求助?哪些是违规求助? 2871136
关于积分的说明 8174143
捐赠科研通 2538111
什么是DOI,文献DOI怎么找? 1370336
科研通“疑难数据库(出版商)”最低求助积分说明 645783
邀请新用户注册赠送积分活动 619564